- Home
- EPAC vs ZLAB Comparison
EPAC vs ZLAB Comparison
Compare EPAC & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPAC
- ZLAB
- Stock Information
- Founded
- EPAC 1910
- ZLAB 2013
- Country
- EPAC United States
- ZLAB China
- Employees
- EPAC N/A
- ZLAB N/A
- Industry
- EPAC Industrial Machinery/Components
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- EPAC Technology
- ZLAB Health Care
- Exchange
- EPAC Nasdaq
- ZLAB Nasdaq
- Market Cap
- EPAC 2.4B
- ZLAB 1.8B
- IPO Year
- EPAC N/A
- ZLAB 2017
- Fundamental
- Price
- EPAC $44.59
- ZLAB $31.24
- Analyst Decision
- EPAC Strong Buy
- ZLAB Strong Buy
- Analyst Count
- EPAC 1
- ZLAB 4
- Target Price
- EPAC $35.00
- ZLAB $52.50
- AVG Volume (30 Days)
- EPAC 388.1K
- ZLAB 976.3K
- Earning Date
- EPAC 10-15-2024
- ZLAB 11-12-2024
- Dividend Yield
- EPAC 0.09%
- ZLAB N/A
- EPS Growth
- EPAC 91.76
- ZLAB N/A
- EPS
- EPAC 1.56
- ZLAB N/A
- Revenue
- EPAC $589,510,000.00
- ZLAB $322,711,000.00
- Revenue This Year
- EPAC $10.55
- ZLAB $48.34
- Revenue Next Year
- EPAC $5.46
- ZLAB $47.12
- P/E Ratio
- EPAC $28.46
- ZLAB N/A
- Revenue Growth
- EPAC N/A
- ZLAB 28.16
- 52 Week Low
- EPAC $27.06
- ZLAB $13.48
- 52 Week High
- EPAC $45.17
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- EPAC 63.60
- ZLAB 70.41
- Support Level
- EPAC $44.07
- ZLAB $31.52
- Resistance Level
- EPAC $45.17
- ZLAB $36.60
- Average True Range (ATR)
- EPAC 1.20
- ZLAB 1.36
- MACD
- EPAC 0.03
- ZLAB 0.34
- Stochastic Oscillator
- EPAC 91.78
- ZLAB 58.60
About EPAC Enerpac Tool Group Corp.
Enerpac Tool Group, previously known as Actuant, provides high-precision tools, controlled-force products, and solutions for precise heavy lifting. The company operates through two segments: industrial tools and services and other. It categorizes its revenue into two parts: product sales and services, which include manpower services and rentals. Product sales is the largest contributor to the company's total revenue. Geographically, the company operates in the United States, Asia, Australia, Europe, Middle East, and other areas. The U.S. makes up the largest contribution to the company's total revenue.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.